MATRIXX Software Teams Up with Hewlett Packard Enterprise to Deliver Real-time 'Monetization-as-a-Service' to CSPs
24.11.2020 14:00:00 EET | Business Wire | Press release
MATRIXX Software, the global leader in 5G monetization solutions, has collaborated with Hewlett Packard Enterprise (HPE) to bring MATRIXX Digital Commerce to Communications Service Providers (CSPs) via HPE GreenLake, an elastic-as-a-service platform that can run on-premises, at the edge or in a colocation.
MATRIXX Digital Commerce provides a cloud native, real-time converged charging and commerce platform that enables CSPs to compete at web scale. Unique in its offering, MATRIXX makes it possible for CSPs to move quickly, engage digitally and operate more efficiently. Industry-leading service providers such as Dish, Swisscom, Orange, and Three have chosen MATRIXX as their future proof monetization solution as they evolve to cloud native architectures and develop new 5G business models for B2C, B2B and B2B2X.
The demand for and consumption of high speed, high quality network resources and value-added services has skyrocketed this year and will continue to do so as CSPs invest in 5G rollouts. To accelerate the delivery of new services, CSPs are increasingly turning to the cloud to provide the operational agility required to support rapid and continuous development and deployment of new services and offerings. By leveraging HPE GreenLake, service providers benefit from combining the agility and economics of public cloud with the security and performance of on-premises infrastructure required by a mission critical, high volume, low latency application such as MATRIXX Digital Commerce.
“We are excited to be collaborating with MATRIXX Software to deliver their innovative charging and commerce platform,” said Claus Pedersen, VP and GM, Worldwide Telco Infrastructure at HPE. “Delivering MATRIXX as-a-service is another proof point of HPE’s ability to deliver business advantage to CSPs whilst freeing them from the Capex investments and the daily cost and complexity of managing these applications on-premises. We deliver these advantages on HPE’s proven carrier-grade infrastructure whilst enabling our customers to flexibly scale the capacity to their business needs.”
“We are thrilled to be collaborating with HPE to bring disruptive propositions to the highly competitive CSP market,” said Marc Price, CTO, MATRIXX Software, “Together, MATRIXX and HPE deliver state-of-the-art solutions that enable CSPs to focus on commercial and technology innovations so they can quickly capture the imagination of their customers and increase market share.”
HPE GreenLake Cloud Services provide customers with a powerful foundation to drive digital transformation through an elastic-as-a-service platform that can run on-premises, at the edge, or in a colocation facility. HPE GreenLake combines the simplicity and agility of the cloud with the governance, compliance, and visibility that comes with hybrid IT. HPE GreenLake offers a range of cloud services that accelerate innovation, including cloud services for compute, container management, data protection, HPC, machine learning operations, networking, SAP HANA, and storage, VDI, and VMs. The HPE GreenLake Cloud Services business is rapidly growing with over $4 billion USD in total contract value, over 700 partners selling HPE GreenLake, and more than 1000 customers in all industry sectors and sizes including Fortune 500 companies.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS) enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005101/en/
Contact information
Jennifer Kyriakakis
mediainquiry@matrixx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom